Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of VIR-2218, VIR-3434, and PEG-IFNα in Chronic Hepatitis B Virus Infection
2021-001033-39Phase 2Active
- Sponsor
- Vir Biotechnology
- Start
- Jul 2021
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of elebsiran, tobevibart and interferon alfa in Chronic Hepatitis B (CHB), sponsored by Vir Biotechnology. Primary endpoints: Safety and tolerability of VIR-2218, VIR-3434, and/or PEG-IFNα regimens and Effect on serum hepatitis B surface antigen (HBsAg). Started Jul 2021; status: active.
02
Drugs
elebsirantobevibartinterferon alfa
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2021-001033-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001033-39.